Isotope therapy

The Norwegian Institute of Public Health (NIPH) has published a health technology assessment of 177Lutetium-based peptide receptor radionuclide therapy for treating neuroendocrine tumors

06

Jul 2018

Norwegian Institute of Public Health (NIPH) conducted a full health technology assessment (HTA) of Peptide receptor radionuclide therapy (PRRT) using 177Luthetium (177Lu-PRRT) on the request from payers (“New methods” framework for introduction of innovations in Norway). Read more